Company intelligence / Profile preview

AqueSys

Aliso Viejo / Orange County, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

AqueSys developed the XEN Gel Stent/XEN45—a minimally invasive soft collagen-derived gelatin microshunt for treating glaucoma. International trials demonstrated significant lowering of intraocular pressure with a favorable safety profile. The device received CE mark and approvals outside the US before being acquired by Allergan during its pivotal US trial phase.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

XEN45

Commercial

Indications: Glaucoma, Primary open angle glaucoma

Beyond the preview

Go deeper on AqueSys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AqueSys.

Explore the full profile